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We have previously reported that mild TBI created by focal left-side cranial blast
in mice produces widespread axonal injury, microglial activation, and a variety of
functional deficits. We have also shown that these functional deficits are reduced by
targeting microglia through their cannabinoid type-2 (CB2) receptors using 2-week daily
administration of the CB2 inverse agonist SMM-189. CB2 inverse agonists stabilize
the G-protein coupled CB2 receptor in an inactive conformation, leading to increased
phosphorylation and nuclear translocation of the cAMP response element binding protein
(CREB), and thus bias activated microglia from a pro-inflammatory M1 to a pro-healing
M2 state. In the present study, we showed that SMM-189 boosts nuclear pCREB levels
in microglia in several brain regions by 3 days after TBI, by using pCREB/CD68 double
immunofluorescent labeling. Next, to better understand the basis of motor deficits and
increased fearfulness after TBI, we used unbiased stereological methods to characterize
neuronal loss in cortex, striatum, and basolateral amygdala (BLA) and assessed how
neuronal loss was affected by SMM-189 treatment. Our stereological neuron counts
revealed a 20% reduction in cortical and 30% reduction in striatal neurons bilaterally
at 2–3 months post blast, with SMM-189 yielding about 50% rescue. Loss of BLA
neurons was restricted to the blast side, with 33% of Thy1+ fear-suppressing pyramidal
neurons and 47% of fear-suppressing parvalbuminergic (PARV) interneurons lost, and
Thy1-negative fear-promoting pyramidal neurons not significantly affected. SMM-189
yielded 50–60% rescue of Thy1+ and PARV neuron loss in BLA. Thus, fearfulness
after mild TBI may result from the loss of fear-suppressing neuron types in BLA, and
SMM-189 may reduce fearfulness by their rescue. Overall, our findings indicate that
SMM-189 rescues damaged neurons and thereby alleviates functional deficits resulting
from TBI, apparently by selectively modulating microglia to the beneficial M2 state.
CB2 inverse agonists thus represent a promising therapeutic approach for mitigating
neuroinflammation and neurodegeneration.
Keywords: traumatic brain injury, neuron loss, neuron rescue, cerebral cortex, striatum, basolateral amygdala,
cannabinoid type-2 receptor inverse agonist
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INTRODUCTION
Mild traumatic brain injury (TBI) occurs frequently as an
outcome from military, sports, and recreational activities, and
vehicular accidents, and can lead to a variety of adverse sensory,
motor, cognitive and emotional outcomes (Faul et al., 2010;
Risdall andMenon, 2011; Johnson et al., 2013). Mild TBI involves
either brief or no loss of consciousness and causes minimal
overt brain destruction, but produces widespread axonal injury
that is commonly referred to as “diffuse” axonal injury, and sets
in motion subsequent secondary degenerative events (Bazarian
et al., 2013; Johnson et al., 2013; Smith et al., 2013b). The initial
injury appears to stem from the compressive, tensile, and shear
forces exerted on neural tissue by the concussive force created
by a blow to the head with a blunt object, a blast shock wave, or
a rapid head acceleration—deceleration (Namjoshi et al., 2013).
Although a variety of treatments have been tested in animal
models and human clinical trials (Xiong et al., 2013), effective
therapies have not been developed. Since microglial activation
is one of the secondary events that appears to worsen the
outcome after mild TBI (Kelley et al., 2007; Redell and Dash,
2007; Cao et al., 2012; Das et al., 2012; Kumar and Loane, 2012;
Patterson and Holahan, 2012; Perez-Polo et al., 2013; Smith et al.,
2013a), we have evaluated the benefits of a novel pharmacological
approach for reducing the harmful effects of activated microglia
(Reiner et al., 2015).
We created mild TBI in mice using a focal blast model (Heldt
et al., 2014; Guley et al., 2016). As our pharmacological approach,
we modulated activated microglia via their cannabinoid type
2 receptors (CB2) (Schomberg and Olson, 2012; Cherry et al.,
2014). CB2 receptors are typically expressed at very low levels in
brain, are more concentrated in microglia than neurons, and are
thus non-psychotropic, in contrast to cannabinoid type 1 (CB1)
receptors (Benito et al., 2003; Stella, 2010; Baek et al., 2013).
Activated microglia, however, rapidly increase their expression
of CB2 receptors (Benito et al., 2003; Ashton and Glass, 2007;
Stella, 2010; Schomberg and Olson, 2012; Baek et al., 2013; Donat
et al., 2014), and so drugs acting on CB2 are especially promising
for selectively targeting microglia for therapeutic purposes.
CB2 inverse agonists in particular represent a unique class
of ligands with promise for beneficially modulating microglia
to treat TBI (Lunn et al., 2006, 2008). CB2 inverse agonists
stabilize CB2 receptors in an inactive state, which are otherwise
constitutively active, and reduce adenylyl cyclase inhibition and
thereby increase cAMP production (Atwood et al., 2012). This in
turn leads to downstream activation of protein kinase A, which
phosphorylates the cAMP response element binding protein
(CREB). Increased phosphorylation and nuclear translocation of
CREB appear to bias activated microglia from the M1 toward the
M2 state, and thus underlie the anti-inflammatory and pro-repair
effects of CB2 inverse agonists (Lunn et al., 2006, 2008; Lawrence
and Natoli, 2011; Presley et al., 2015).
We have previously tested if the selective CB2 inverse agonist
SMM-189, which was developed in one of our laboratories and
has striking efficacy in reducing the M1 features and increasing
the M2 features of human and murine microglia in vitro (Presley
et al., 2015; Reiner et al., 2015), could improve the outcome after
mild TBI in our mouse model. We have shown that a 2-week
daily treatment with SMM-189 after mild TBI greatly attenuates
the motor deficits, visual deficits and increased fearfulness that
are otherwise evident 2–6 weeks after the traumatic event (Reiner
et al., 2015).We have also found that the decrease in some of these
functional abnormalities was associated with reduced pathology
in neural structures associated with these functions. For example,
rescue of visual deficits was associated with reduced thinning of
the retina, and the attenuation in fearfulness was associated with
the rescue of at least one population of neurons in the basolateral
amygdala (BLA) that promotes fear. Our previous work has thus
shown that treatment with a CB2 receptor inverse agonist that
biases brainmicroglia from a pro-inflammatoryM1 phenotype to
a pro-healing M2 phenotype is beneficial after mild TBI (Reiner
et al., 2015).
The present study had two goals. First, we sought to determine
if mild TBI resulted in the loss of neurons in brain regions linked
to motor functions and fear control, to better understand the
basis of the motor and emotional deficits observed in our model.
To this end, we used blinded stereology in mice 2–3 months after
mild TBI to analyze neuron loss in cerebral cortex and striatum
because of their role in motor control, and several neuron types
in the BLA that are differentially involved in fear regulation
and expression. Secondly, we evaluated the efficacy of SMM-
189 in rescuing these neuron types, both to better understand
the basis of the functional recovery SMM-189 provides, and also
to further assess the contributions of the neuronal loss to the
functional deficits. As part of this, we confirmed that SMM-
189 treatment increased levels of nuclear pCREB in microglia
in the brain systems under study, which would thereby bias
the microglia toward an M2 state. Overall, our findings indicate
diffuse neuron loss as a contributor to functional deficits in our
TBImodel, and they support the use of CB2 inverse agonists as an
approach for reducing neuron loss and/or injury after mild TBI
and attenuating functional deficits.
MATERIALS AND METHODS
Animals
Three-month old male mice were subjected to single left-side
blasts of 0-psi (sham) or 50–60-psi above atmospheric pressure
and the outcome evaluated in two sets of studies. In one
set of studies, we assessed if SMM-189 treatment increases
nuclear pCREB levels in microglia, using pCREB/CD68 double
immunofluorescent labeling of brain sections from mice 3 days
either after blast alone or after blast followed by SMM-189
treatment. In a second set of studies, we evaluated the TBI
outcome for neuron abundance in cerebral cortex, striatum
and BLA histologically 2–3 months after blast, to allow time
for any neuron loss to develop, comparing mice with and
without SMM-189 treatment. Two strains of mice were used,
C57BL/6 mice and reporter mice (on a C57BL/6 background)
conditionally expressing enhanced yellow fluorescent protein
(EYFP) in Thy1-expressing telencephalic neurons of the emx1
lineage (Gorski et al., 2002; Bareyre et al., 2005). The EYFP
reporter mice were used to histologically evaluate the effects of
blast on the Thy1+ vs. Thy1−negative subset of functionally
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distinct excitatory pyramidal neurons of BLA (Heldt et al., 2014;
Reiner et al., 2015). The C57BL/6 mice were either purchased
from Jackson Laboratories (JAX; Bar Harbor, ME), and/or taken
from a colony maintained from C57BL/6 founders from JAX at
the University of Tennessee Health Science Center (UTHSC).
Floxed Thy1-EYFP reporter mice (purchased from JAX) and
emx1-Cre driver mice (purchased from the Mutant Mouse
Regional Resource Consortium) were maintained as colonies at
the UTHSC, and bred to one another to produce the Thy1-
EYFP+/emx1-cre+ progeny used for the experiments. Mice
were injected intraperitoneally daily with 6 mg/kg SMM-189
or vehicle (ethanol:Cremophor:0.9% saline; 5:5:90) for 14 days
beginning 2 h after 50–60 psi or 0-psi (sham) blast in the case
of neuronal loss studies and for 3 days in the case of pCREB
studies. The dose used was chosen based on studies of uptake
in rodent brain of structurally similar tri-aryl CB2 compounds
(Fujinaga et al., 2010), which proved effective in our prior
study (Reiner et al., 2015), and which is more than adequate
for CB2 receptor activation given its 121.3 nM affinity (Presley
et al., 2015). Note that although Cremophor has been linked
to neuropathy when used as a vehicle for anti-cancer drugs
(Gelderblom et al., 2001), the dose of Cremophor used here was
below the maximum recommended dose for rodents, which is
not known to have side effects (Neervannan, 2006). Consistent
with this, no abnormalities were seen in optic nerve of mice
following 2 weeks of Chremophor vehicle treatment in a prior
study by us (Reiner et al., 2015). In addition, the number of
cortical and striatal neurons in mice that received sham blast
and Cremophor vehicle in the present study did not differ from
those in our prior study (Guley et al., 2016) that received sham
blast and no vehicle, and there were also no differences in
body weight. All studies were performed in accordance with an
UTHSC Institutional Animal Care and Use Committee approved
protocol and complied with the National Institutes of Health and
Society for Neuroscience guidelines. The mice analyzed here for
neuron loss included some that had been used in our initial study
of functional and morphological aspects of SMM-189 benefit (16;
Reiner et al., 2015). For studies of neuron loss in cortex and
striatum, 3 mice were analyzed per group (0-psi vehicle, 50-psi
vehicle, and 50-psi, SMM-189), with amean post-blast survival of
75.3, 75.7, and 77.0 days, respectively, per group. For BLA neuron
loss, 4 mice were analyzed per group, with a mean post-blast
survival of 69.3, 67.5, and 58.0 days, respectively, per group.
TBI Methods
The overpressure air blast was delivered by a small horizontally
mounted air cannon system (Heldt et al., 2014; Guley et al., 2016),
consisting of a modified paintball gun (Invert Mini, Empire
Paintball, Sewell NJ), pressurized air tank, and x-y table secured
onto a medium-density fiberboard. The original paintball gun
barrel with a 13mm aperture was replaced with a machined
barrel with a 6.5 mm diameter aperture, to increase output
pressure. The air blast pressures from the paintball gun were
controlled by adjusting the output from a pressurized air tank, as
monitored by a gun input pressure gauge. The part of the mouse
exposed to the blast was restricted to a 7.5mm diameter mid-
cranial territory, as described previously (Guley et al., 2016). The
exposed region was the parietal area of the left side of the head
between the ear and the eye, encompassing that part of the skull
overlying the forebrain. A foam rubber sleeve surrounding the
mouse cushioned the non-blast side of the mouse, to stabilize it
and minimize head displacement. Prior to blast exposure, mice
were anesthetized with avertin (400mg/kg body weight), the fur
of the parietal region of the left side of the head shaved, and the
mouse secured in a holder as described previously (Guley et al.,
2016). TBI mice used for study of cortex and striatum received
50-psi blast, while TBI mice used for study of BLA received 60-
psi blast. All of the same procedures were followed for sham-blast
mice (0-psi), except that the mouse was shielded from the blast
by a metal plate inserted between it and the gun nozzle. Mice
received 35mg/ml Tylenol in their drinking water for 24 h after
blast.
Morphological Methods
Histological analysis was carried out on fixed brain tissue to
determine the effects of TBI on the brain, and the remedial effects
of SMM-189. Either 3 days or 2–3 months after blast, mice were
deeply anesthetized (avertin; 0.2ml/g body weight), the chest
opened, and 0.1ml of heparinized saline (800 U.S.P. units/ml)
injected into the heart. Mice were then perfused transcardially
with 40ml of 0.9% NaCl in 0.1M sodium phosphate buffer at
pH 7.4 (PB), followed by 200ml of 4% paraformaldehyde, 0.1M
lysine-0.1M sodium periodate in 0.1M PB at pH 7.4 (PLP).
The brain was removed, post-fixed overnight, a pin inserted
longitudinally into the right side to distinguish left blast-exposed
side from right non-exposed side, and then stored in a 20%
sucrose/10% glycerol solution at 4◦C. The fixed brains were
sectioned frozen on a sliding microtome in the transverse plane
at 35 µm, and each brain collected as either 6 (for BLA) or 12
separate series (for cortex and striatum) in 0.1M PB with 0.02%
sodium azide. At least one series of brain sections from each
mouse was mounted as sectioned and stained with cresyl violet.
One or more series were immunostained for the pan-neuronal
marker NeuN using a mouse monoclonal antibody (Millipore
Corp., Billerica, MA) and peroxidase-antiperoxidase (PAP)
procedures as described previously (Reiner et al., 2015; Guley
et al., 2016), and in the case of 2–3month survival mice employed
to count all neuronal perikarya in cerebral cortex, striatum and
BLA. Thy1+ pyramidal neurons of BLA in the Thy1 reporter
mice were visualized for transmitted light microscopic study
using a mouse monoclonal antibody against green fluorescent
protein (Rockland Inc, Gilbertsville, PA), which crossreacts with
EYFP due to the high similarity of their antigenic determinants.
We detected PARV+ interneurons in BLA using a mouse
monoclonal anti-PARV antibody (Sigma-Aldrich, St. Louis,MO),
as described previously (Deng et al., 2007). Thy1+ pyramidal
neurons and PARV+ interneurons in BLA were each visualized
using PAP procedures in separate series of coronal sections. To
evaluate CREB phosphorylation by SMM-189, we used a rabbit
anti-pCREB antibody (#p1010-133; PhosphoSolutions, Aurora,
CO) and anti-rabbit IgG conjugated to Alexa-594 (Molecular
Probes; Eugene, OR), in conjunction with a rat anti-CD68
antibody (#ab53444; Abcam, Cambridge, MA) and anti-rat IgG
conjugated to Alexa-647 (Molecular Probes; Eugene, OR) to
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FIGURE 1 | Images showing the effect of SMM-189 treatment on pCREB expression in microglia after blast. Confocal image pairs, one showing
immunostaining for pCREB and CD68 and the other showing pCREB and DAPI, in left BLA and SNr in a blast alone mouse (A,B,E,F) compared to a SMM-189
treated blast mouse (C,D,G,H) at 3 days post blast. The CD68/pCREB double labeling shows microglia with CREB activation (i.e., nuclear pCREB; yellow arrows).
The DAPI staining (pseudo-colored red for ease of viewing) reveals nuclei. Note that the nuclei of neurons are distinctly larger than those of microglia. The nuclei of all
microglia in the blast mouse lack prominent pCREB (thin white arrows), whereas in the SMM-189 treated blast mouse all microglia are rich in nuclear pCREB (yellow
arrows). Thus, SMM-189 treatment after blast results in CREB activation in microglia in BLA and SNr.
identify microglia. Nuclei were visualized by DAPI staining.
Sections were mounted on gelatin-coated slides and coverslipped
with ProLong R© antifade medium (Molecular Probes, Eugene,
OR). Sections were viewed and images captured using a Zeiss 710
confocal laser-scanning microscope.
Neuron Counts
Unbiased, blinded stereological neuron counts were carried out
using Stereo Investigator (Micro-Brightfield, Colchester, VT)
with the optical fractionator method, as described previously
(Reiner et al., 2012; Guley et al., 2016). Stereology also provided
information on the volumes of the structures examined. The
results for different groups ofmice were compared using ANOVA
followed by planned comparisons with post-hoc Bonferroni tests.
No inhomogeneity of variances was detected by the Levene
statistic for any of the data sets. Neuron counts for cortex
and striatum were obtained using a one-in-twelve series of
coronal sections immunolabeled for NeuN from C57BL/6 mice
that had previously been used in rotarod assessments of motor
performance (Reiner et al., 2015). The cortical field counted
extended from the pial surface to the external capsule, and from
the midline to the rhinal fissure. The striatum was defined by
the contours of the external capsule and globus pallidus, and
included nucleus accumbens. Cortex and striatum counts were
performed from the rostral end of each to the level of the passage
of the internal capsule into the thalamus, and thus included all
but the most caudal ∼25% of cortex and the most caudal ∼10%
of striatum. We have interpreted a reduction in the number of
immunolabeled neurons at 2–3 months post-blast to represent
neuron loss, as is routinely the case (Kordower et al., 2001; Shi
et al., 2004; Unal-Cevik et al., 2004; Avramescu et al., 2009; Reiner
et al., 2012; Zhang et al., 2015), although the possibility exists that
the loss of immunolabeling could reflect neuronal dysfunction.
To evaluate the impact of neuron loss/rescue on motor function,
we used regression analysis to determine if neuron abundance
was correlated with rotarod performance, as determined in the
previously reported functional assessment at 2 weeks post-blast.
Neuron counts for BLA were obtained from Thy1 reporter mice,
which had not been tested for fearfulness, using separate one-in-
six series of brain sections immunolabeled for NeuN, Thy1 (i.e.
GFP) or PARV, and covered the full extent of rostral BLA.
RESULTS
Activation of CREB by SMM-189
As an inverse agonist, SMM-189 biases the CB2 receptor
conformation to an inactive state (Presley et al., 2015), leading to
phosphorylation of CREB, which, in turn, promotes transcription
of M2 genes and represses transcription of M1 genes (Atwood
et al., 2012). To examine the effects of SMM-189 on microglia
in the brain, we immunolabeled for pCREB in conjunction with
CD68 to visualize microglia. Confocal images from blast-alone
mice 3 days after blast revealed no evident pCREB in the vast
majority of microglia (>95%), with microglial cell bodies and
nuclei confirmed as CD68+ and DAPI+. This was true for all
brain regions examined, notably the BLA, the striatum and its
major projection target, the substantia nigra pars reticulata (SNr),
and for the axonal outflow of cerebral cortex in the internal
capsule, as shown in Figures 1, 2. By contrast, in mice 3 days
after blast with daily SMM-189, most, if not all, microglia in
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these brain regions were enriched in nuclear pCREB. Moreover,
some microglia, notably in the internal capsule, had a rod-
like morphology (Figure 2C). Some of the rod-like microglia
were aligned parallel to axons in the internal capsule and some
seemingly parallel to blood vessels. These rod-like microglia are
reminiscent of microglia that become aligned along scratches in
the tissue culture substratum, which are thought to correspond to
an M2 state (Tam and Ma, 2014). Thus, SMM-189 acted on brain
microglia as expected and consistent with its actions onmicroglia
in vitro (Presley et al., 2015; Reiner et al., 2015).
Cortical and Striatal Neuron Loss after
Mild TBI Is Rescued by SMM-189
Examination of cresyl violet or NeuN stained sections did not
reveal any obvious foci of neuronal loss or generalized neuron
loss in cerebral cortex or striatum on either side of the brain
2–3 months after a 50-psi blast (Figure 3). However, blinded
stereological neuron counts showed a bilateral loss of about 20%
of neurons in the cerebral cortex (left: p= 0.025; right: p= 0.021),
and a bilateral loss of about 30% of striatal neurons (left: p =
0.00048; right: p = 0.003) in mice that had received 50-psi blasts
compared to those that had received 0-psi blasts (Figure 4A).
The overall volumes of the cerebral cortex and the striatum were
slightly, but not significantly, less inmice with 50-psi blast than in
sham mice (Figure 4B). Daily treatment with SMM-189 for the
2 weeks after blast significantly reduced the cortical and striatal
neuron loss, by about 50% in both cases (Figure 4A). For cortex,
neuron counts in SMM-189 treated mice with 50-psi blast were
no longer significantly different than in the vehicle-treated sham
blast mice (left: p = 0.691; right: p = 0.745), and trended toward
being more than in vehicle-treated 50-psi mice (left: p = 0.133;
right: p = 0.103). For left striatum, neuron counts in SMM-189
treated mice with 50-psi blast were significantly more than in
vehicle-treated 50-psi mice (p=0.020), although they remained
significantly less than in the vehicle-treated sham blast mice (p
= 0.015). For right striatum as well, neuron counts in SMM-189
treated mice with 50-psi blast were significantly more than in
vehicle-treated 50-psi mice (p= 0.047), but in this case they were
also statistically indistinguishable from that in the vehicle-treated
sham blast mice (p= 0.094).
We previously reported that blast resulted in impaired
rotarod performance and that SMM-189 treatment produced
partial rescue of this motor deficit (Reiner et al., 2015). We
used regression analysis to examine the relationship between
rotarod performance and the extent of neuronal loss and rescue,
combining the data for all three groups of mice (i.e., sham mice,
and the TBI mice, with and without SMM-189), as shown in
Figure 5. We found that cortical neuron abundance for the two
sides of the brain taken together was highly correlated with
rotarod performance (r = 0.6443; p = 0.032). Similarly, striatal
neuron abundance for both sides of the brain combined was also
highly correlated with rotarod performance (r = 0.5908; p =
0.047). These results are consistent with the idea that the loss of
cortical and striatal neurons contributed to the rotarod deficit
produced by blast, and that their partial rescue by SMM-189
contributed to the partial rescue of rotarod performance.
FIGURE 2 | Images showing the effect of SMM-189 treatment on
pCREB expression in microglia in the left internal capsule after blast.
Confocal images showing immunostaining for pCREB and CD68 in a blast
alone mouse (A) compared to a SMM-189-treated blast mouse (B,C) at 3
days post blast. DAPI staining (not shown) was used to identify nuclei. The
nuclei of all microglia lack prominent pCREB in the blast mouse (white arrows),
but all are rich in pCREB in the SMM-189-treated mouse (yellow arrows). Note
that some microglia exhibit prominent CD68 expression and a rod-like
morphology (C) after SMM-189 treatment, and some of these are aligned
parallel to axons descending from the cerebral cortex.
FIGURE 3 | Images showing the effect of TBI and SMM-189 on NeuN+
neurons in left cerebral cortex and striatum at 2–3 months post-blast.
Neither focal nor diffuse neuron loss is evident in the 50-psi vehicle-treated
cortex or striatum, compared to 0-psi vehicle-treated cortex and striatum.
Similarly, the abundance of cortical and striatal neurons does not appear
obviously different in the 50-psi SMM-189 treated mice from that in either of
the other two groups. Magnification is the same for all panels. Stereology,
nonetheless, revealed neuron loss in both in 50-psi vehicle-treated mice.
BLA Neuron Loss after TBI Is Rescued by
SMM-189
BLA is composed primarily of Thy1+ and Thy1-negative
pyramidal neurons, with several types of interneurons making
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FIGURE 4 | Graphs showing the effect of TBI and SMM-189 on NeuN+ neurons (A) and on volumes (B) in cerebral cortex and striatum. Stereological
counts (A) revealed bilateral neuron loss in the 50-psi vehicle-treated cortex and striatum, and significant rescue after SMM-189 treatment. Red asterisks indicate a
significant difference between vehicle-treated 50-psi mice and vehicle-treated 0-psi mice. Green asterisks indicate a significant difference between SMM-189 and
vehicle-treated 0-psi mice. Asterisks above bars spanning the SMM-189 and vehicle-treated 50-psi mice columns indicate a significant difference between these two
conditions. No significant volume loss is evident in the 50-psi vehicle-treated cortex or striatum (B), compared to 0-psi vehicle-treated cortex and striatum, although a
trend toward reduction is seen.
up the remaining 10% of the total neuronal population. The
Thy1+ pyramidal neurons and the PARV+ interneurons are
both reported to play a role in suppressing fear (Myers et al.,
2006; Herry et al., 2008; Heldt et al., 2012; Jasnow et al.,
2013). For this reason, and because we had previously observed
that mild TBI results in a loss of Thy1+ neurons (Reiner
et al., 2015), in the present study we used stereological neuron
counting methods to more fully analyze the effects of TBI and
SMM-189 treatment on neuron-type specific pattern of loss in
BLA. As a first step, we determined the relative abundance of
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FIGURE 5 | Regression analysis showing the relationship between rotarod performance and the extent of cortical (A) and striatal (B) neuronal loss and
rescue, combining the data for all three groups of mice.
several of the different major neuron types in BLA. Using a
Thy1-EYFP reporter mouse to visualize the Thy1+ neurons,
and immunostaining a separate series of sections for NeuN to
visualize the total neuronal population, we found that 38.1%
of BLA neurons are Thy1+ neurons. As pyramidal neurons
are thought to make up about 90% of the total population of
BLA neurons (Godavarthi et al., 2014; Wolff et al., 2014), this
suggests that Thy1-poor pyramidal neurons constitute 51.9% of
all BLA neurons (90–38.1%). We also found that 3.7% of all BLA
neurons are PARV+. With interneurons representing about 10%
of all BLA interneurons, 6.3% of BLA neurons must correspond
to the separate interneuron types that contain somatostatin,
cholecystokinin, or vasoactive intestinal polypeptide (Rainnie
et al., 2006; Muller et al., 2007).
Blasts of 60-psi to the left side of the head resulted in 20.1%
overall loss (p = 0.000069) of NeuN-immunostained neurons
from the left BLA (Figures 6A,B, 7A), with no significant change
in the volume of left BLA. Thy1+ pyramidal neurons showed
a 33.3% loss (p = 0.000014) in vehicle-treated 60-psi mice
compared to vehicle-treated sham blast mice (Figures 6D,E, 7A).
Similarly, PARV+ interneurons showed a 42.1% neuron loss
(p = 0.00001; Figures 6G,H, 7A). As the Thy1+ pyramidal
neurons and the PARV+ interneurons of BLA are involved
in reduction and extinction of learned fear (Myers et al.,
2006; Herry et al., 2008; Heldt et al., 2012; Jasnow et al.,
2013), their loss is likely to contribute to the increased learned
contextual fear and diminished fear extinction exhibited by
mice that we had subjected to 50–60 psi blasts (Heldt et al.,
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2014; Reiner et al., 2015). By contrast, the remaining neurons
(i.e., Thy1-negative/PARV-negative), which largely constitute
the Thy1-negative pyramidal neurons of BLA, showed only a
small reduction that was not statistically significant (∼10% loss;
p = 0.109; Figure 7A). Since the non-Thy1+ pyramidal neurons
promote fear, their preferential preservation, together with the
substantial loss of the Thy1-enriched fear-reducing pyramidal
neurons may explain why TBI increases fear in our model
(Haubensak et al., 2010; Herry and Johansen, 2014; Lüthi and
Lüscher, 2014).
We found that SMM-189 treatment significantly rescued
the TBI-related loss of both Thy1+ neurons and PARV+
interneurons, returning these to 80.3 and to 82.4% of sham
abundance, respectively (Figures 6D–I, 7A). The abundance of
Thy1+ BLA neurons in SMM-189 treated 60-psi mice was
significantly greater than in vehicle-treated 60-psi mice (p =
0.010), although it remained less than in vehicle-treated 0-psi
mice (p = 0.001). Similarly, the abundance of PARV+ BLA
neurons in SMM-189 treated 60-psi mice was greater than in
vehicle-treated 60-psi mice (p = 0.005), but still less than in
vehicle-treated 0-psi mice (p= 0.034). SMM-189 trended toward
rescue of overall BLA neuron loss, as reflected in the NeuN
immunolabeling (Figures 6A–C), reducing it from 79.9% to
87.2% (p = 0.054842). By contrast, with SMM-189 treatment,
the Thy1-negative/PARV-negative BLA neurons were found to be
92.0% of sham-vehicle abundance—not significantly more than
in vehicle-treated 60-psi mice (p = 1.000), nor significantly less
than in vehicle-treated 0-psi mice (p= 0.240; Figure 7A).
In contrast to left BLA, no significant loss was observed in
the right BLA for the Thy1+ neurons (p = 1.000), the PARV+
neurons (p= 1.000), or the Thy1-negative/PARV-negative NeuN
neurons (p = 0.611; Figure 7B), or for right BLA volume as
measured in the sections used for Thy1, PARV or NeuN neuron
counts. Finally, the abundance of each of these three neuron
types in right BLA did not differ significantly between SMM-189
treated blast mice and the sham mice.
DISCUSSION
Neuronal Loss with TBI
Cerebral Cortex and Striatum
We have previously reported that our model of mild TBI
produces diffuse axonal injury, as evidenced by the presence of
swollen axonal bulbs at a few days, and degenerating axons at
1–2 weeks after blast (Heldt et al., 2014; Guley et al., 2016). As
in humans and in other animal models of TBI (Petras et al.,
1997; Shitaka et al., 2001; Koliatsos et al., 2011; MacDonald et al.,
2011; Johnson et al., 2013; Morey et al., 2013; Xu et al., 2016),
damaged axons were most prevalent in the major white fiber
tracts, where their parallel arrangement is thought to make them
especially vulnerable to breakage by the stretch and shear forces
produced when the blast pressure wave is conducted through the
brain parenchyma (Smith et al., 2013b). In turn, this widespread
axonal damage may contribute to the apparently diffuse loss of
neurons we report here for the cerebral cortex and striatum, as
well as to the neuron loss and atrophy observed in cortex and
striatum after closed-head TBI in humans (Wilde et al., 2007;
Maxwell et al., 2010; Leunissen et al., 2014) and after mild TBI
in animal models (Smith et al., 1997; Cho et al., 2013; Sajja
et al., 2013; Goddeyne et al., 2015). The observed neuronal loss
in our study was not obviously localized to a restricted region
and was not evident without stereological neuron counts. It thus
seems unlikely that neuronal loss occurred disproportionately in
a particular region (e.g., frontal, visual, somatosensory, motor, or
medial vs. lateral) or layer of cerebral cortex, or in a particular
region or compartment of the striatum. However, additional
analysis and the use of cell-type specific markers would be
required to determine if there was any loss of interneurons and/or
any preferential loss of a specific subpopulation(s) of projection
neurons from cortex or striatum (Reiner et al., 1998; Hattox and
Nelson, 2007; DeFelipe et al., 2013; Deng et al., 2015). Prior
studies have reported that projection neurons in cortex and
striatum are vulnerable to TBI (Maxwell et al., 2010; Bales et al.,
2011), but interneurons, at least those in the hippocampus, have
been reported to also be vulnerable to TBI (Lowenstein et al.,
1992; Hicks et al., 1993; Smith et al., 1997; Tsuda et al., 2016).
The loss of neurons in the cerebral cortex and striatum
was not only seemingly distributed throughout each, but also
was similar in extent for the two sides of the brain. It may
be that the bilateral neuronal loss stems from bilateral axonal
injury, as both cortex and striatum are composed primarily of
projection neurons possessing long axons, which travel in the
corpus callosum or pyramidal tract and in the ansa lenticularis
or striatonigral tract, respectively (Reiner et al., 1998; Hattox and
Nelson, 2007; Deng et al., 2015). The fact that the pyramidal
tract, ansa lenticularis and striatonigral tract are juxtaposed at
their entry into the thalamus andmidbrain maymake their axons
subject to similar tensile and shear forces at this level of the brain,
and thus bilaterally vulnerable. A possible reason for the greater
extent of neuron loss we find for the striatum as compared to
cortex (∼30 vs. ∼20%) may relate to the higher proportion of
projection neurons in the striatum (∼95%) as compared to the
cerebral cortex (∼80%) (Peters et al., 1985; Reiner et al., 1998;
Bartolini et al., 2013), with all striatal projection neurons, but
only about half of all cortical projection neurons, having axons
that follow a longitudinal trajectory in the brain. Longitudinally
running axons appear to be more susceptible to damage in
our TBI model, in that we observed axonal bulbs and silver-
stained degenerating axons more frequently in the pyramidal
and optic tracts than in the corpus callosum (Heldt et al.,
2014; Guley et al., 2016). Similarly, the pyramidal and optic
tracts are especially vulnerable to axonal injury with closed skull
impact TBI, for example the Marmarou impact acceleration
approach, which also subjects axons to stretch and shear forces
(Kallakuri et al., 2012; Zakaria et al., 2012). Based on published
computer models of TBI biomechanics (Taylor and Ford, 2009;
Laksari et al., 2014), the blast wave created using our system
would be expected to also compress the brain, first on the
targeted left side and then on the contrecoup side as the brain
moves within the skull, and this may further contribute to the
generalized bilateral neuron loss we found. Relatively little is
known, however, about the long-term deleterious consequences
of compressive forces on axons and neuronal cell bodies (Meaney
and Smith, 2011).
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FIGURE 6 | Images showing the effect of TBI and SMM-189 on NeuN+ neurons in left BLA (A–C), on Thy1+ fear-suppressing pyramidal neurons in left
BLA in a Thy1-EYFP reporter mouse (D–F), and on PARV+ interneurons in left BLA (G–I). A reduction in NeuN+ neurons is seen in the 60-psi blast mice (B
compared to A), which trended toward being rescued by SMM-189 treatment (C). Similarly, Thy1+ neurons of left BLA are reduced in the 60-psi blast mice (E), and
rescued in the SMM-189 treated 60-psi blast mice (F), as also true for the PARV+ neurons of left BLA (G–I). Medial is to the right and magnification is the same in all
images.
It should be noted that we previously reported an ∼10% loss
of axons in the dorsal corticospinal (CST) axons at thoracic spinal
cord levels on the right side as compared to the left side following
left side cranial blast (Guley et al., 2016). We also observed
an asymmetry in signs of axonal injury along the descending
pyramidal tracts at the level of the pons, with more on the left
side (Guley et al., 2016). As axons arising from corticospinal
motoneurons (CSMNs) on the left side of the brain cross the
midline at the spinomedullary junction, the results for CST axons
might suggest that damage was limited to the left side of motor
cortex, and at first glance, appear to contradict the bilateral loss
of cortical neurons reported here. However, our analysis of axon
loss, which compared the areas of axons immunostained for
protein kinase C gamma on the two sides, would not rule out the
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FIGURE 7 | Graphs showing the effect of TBI and SMM-189 on neuron types in left BLA (A), and in right BLA (B). Thy1+ pyramidal neurons and PARV+
interneurons are decreased in number in the left BLA of 60-psi blast mice, and are both rescued in the SMM-189 treated mice. By contrast, there was no significant
change in the non-Thy1/non-PARV neurons of left BLA (which are mainly fear-promoting pyramidal neurons) of BLA after TBI. Red asterisks indicate a significant
difference between vehicle-treated 60-psi mice and vehicle-treated 0-psi mice. Green asterisks indicate a significant difference between SMM-189 and vehicle-treated
0-psi mice. Asterisks above bars spanning the SMM-189 and vehicle-treated 60-psi mice columns indicate a significant difference between these two conditions. No
significant changes in Thy1+ pyramidal neurons, PARV+ inhibitory interneurons, or non-Thy1/non-PARV neurons were seen for the right BLA following TBI, with or
without treatment (B).
possibility that CST axons on the left side of the spinal cord were
also lost, just that loss was greater for the right side. Moreover,
CSMNs are estimated to comprise less than 5% of the neurons
in motor cortex (Özdinler et al., 2011) and so a preferential
loss of CSMNs from left but not right motor cortex, would not
significantly affect the overall cortical counts reported here.
The injury produced in our blast model is classified as mild
TBI, based on the absence of obvious contusion or hemorrhaging,
the rapidity with which animals awaken from anesthesia after
TBI, and the absence of any post-TBI torpor. It thus is surprising
to find that 20–30% of neurons had been lost by 2–3 months
after the injury. Few other studies of mild TBI have, however,
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examined this issue. Although some published reports have
shown dying neurons by immunolabeling for activated caspase,
or staining using fluorojade or TUNEL (e.g., Raghupathi et al.,
2002; Longhi et al., 2005; Sajja et al., 2015), these approaches do
not provide information about the ultimate extent of neuronal
loss. Further, in many cases, histological examination of the brain
has been limited to 10 days or less after the TBI event. The
main exceptions are several studies in which researchers, having
observed extensive axonal injury in the optic tract and nerve,
have then counted surviving retinal ganglion cells (Tzekov et al.,
2014; Xu et al., 2016). For example, Xu et al. (2016) reported
30% retinal ganglion cell loss by 10 weeks after impact TBI.
Interestingly this is similar to the amount of loss we found for
the striatum, with its 95% complement of projection neurons,
and is consistent with observations that the majority of axons are
not injured by mild TBI. Other studies have shown substantial
cortical thinning, striatal atrophy, and up to 40% hippocampal
neuron loss as long-term consequences of contusive cortical
injury (Baldwin et al., 1997; Smith et al., 1997). This type of TBI
is, however, severe in that the skull is open and the exposed dura
is impacted. Thus, to the best of our knowledge, no studies other
than our own have examined the consequence of mild TBI for
neuron loss in the brain. It may be that the 20–30% loss we
observed occurs over a time frame of several weeks and that
diffuse neuron loss goes undetected unless stereological analysis
is performed.
Basolateral Amygdala
Neuronal loss in BLA varied in several ways from that in cerebral
cortex and striatum.Most strikingly, it was limited to the targeted
side of the brain rather than occurring bilaterally. BLA is situated
slightly deep and anterior to the center of the area targeted by the
blast region, which corresponds to the thalamus. The presence of
the fluid-filled lateral and third ventricles at this level may alter
the transmission of tensile, shear, and compressive forces from
one side of the brain to the other, and may thereby “protect”
deeper neural structures such as the amygdala on the non-blast
side, as may also the transverse course of its efferent axons
(Gupta and Przekwas, 2013). In addition, the left BLA neuron
loss involved 33.3% reduction in one population of pyramidal
projection neurons (Thy1+) but no significant loss in the other
major population of BLA pyramidal projection neurons (i.e., the
Thy1-negative), as well as a 42.1% loss of PARV interneurons.
The present results are consistent with our prior report of Thy1
neuron loss in BLA after mild TBI (Heldt et al., 2014; Reiner
et al., 2015), and with reports of GABAergic neuron loss from
BLA after controlled cortical impact TBI (Almeida-Suhett et al.,
2014). Although we did not observe neuron loss in the right
BLA, it is nonetheless possible that functional changes occurred
in Thy1 and PARV neurons in right BLA, given that neurons
can be dysfunctional after brain injury or in neurodegenerative
diseases, in the absence of or prior to overt neuron loss (Cohen
et al., 2007; Smith et al., 2013a; Deng et al., 2014).
Mechanisms of Neuron Loss
Taken together, our results for cortex and striatum suggest
that axonal injury may contribute to subsequent neuron death
after TBI, whereas our results for PARV+ interneurons of BLA
indicate that axonal injury is not necessary for neuronal loss
for at least some neuron types in our model. Moreover, the
basis of the differential vulnerability of Thy1+ vs. Thy1-negative
pyramidal neurons of left BLA is uncertain, as both send axons
to the nearby central amygdala, as well as more distantly to the
medial prefrontal cortex (Lüthi and Lüscher, 2014). A variety
of cellular characteristics confer susceptibility to neuronal death
after trauma, for example, a limited ability to buffer calcium or a
high vulnerability to excitotoxic or oxidative injury (McGinn and
Povlishock, 2015; Jayakumar et al., 2016; Tovar-y-Romo et al.,
2016). In addition, neuroinflammation often has detrimental
effects in the aftermath of TBI (Brown and Vilalta, 2015; Loane
and Kumar, 2016) and is likely to contribute to the neuron
loss we find here. Consistent with this possibility, neuron loss
appears to be progressive in our model, as we previously found
∼12% cortical neuron loss at 45 days after blast (Guley et al.,
2016), as compared to the ∼20% loss at 2–3 months post-blast
reported here. We do not know if cortical and/or striatal neurons
continue to die beyond the 3-month time point and, if so, at
what rate. Moreover, we do we know if neuronal death occurs
and is progressive in other regions as well. The additional loss
of ∼8% of cortical neurons between 6 and 10 weeks after the
initial traumatic event cannot readily be explained by damage to
the neurons themselves. Moreover, as will be discussed in more
detail below, that SMM-189 treatment rescued roughly half of
the neurons that would have otherwise been lost, suggests that
the rescued neurons died as consequence of neuroinflammatory
processes. It is possible that yet more neurons may be capable of
rescue, since we do not know if the dose or timing of SMM-189
treatment we used could be further optimized.
Neuronal Loss and Rescue in Cerebral
Cortex and Striatum and Relation to Motor
Deficits
The neuronal loss we find in cerebral cortex and striatum
at 3–4 months is correlated with the rotarod deficits these
mice exhibited at 2 weeks post blast (Guley et al., 2016),
indicating that the injury severity in the 2 weeks after blast
and its rescue with SMM-189 predict the deficits and ultimate
neuron loss. Consistent with this, treatment for 2 weeks after
blast with the CB2 inverse agonist SMM-189 rescues about
half the total number of cortical and striatal neurons that
would have otherwise died, and significantly reduces rotarod
deficits (Reiner et al., 2015). Whether the rescue of cortical
neurons with SMM-189 treatment is the cause or consequence
of the rescue of CST axons that we previously reported (Reiner
et al., 2015) is uncertain. The present results extend on our
prior findings, in that they show that rescue of sensorimotor
deficits causing impaired rotarod performance may be due to
the preservation of cortical and striatal neurons. Much of the
area of the cortex for which counts were obtained corresponds
to somatosensory and motor regions and staying on rotarod
requires sensory-motor coordination. Similarly, the correlation
of striatal neuron abundance with rotarod performance is
consistent with role of striatum, as it is important in movement
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initiation, action sequence coordination, and motor learning
(Deng et al., 2015; Yttri and Dudman, 2016). It is likely that TBI
in our model produces cortical neuron loss throughout the entire
cortex and deficits in functions that we have not assayed, such
as in somesthesis, audition, and memory. Consistent with this,
we have detected electrophysiological abnormalities in prefrontal
cortex, hippocampus, visual cortex and somatosensory cortex as
early as 1 month after blast (Liu et al., 2016). Whether deficits in
memory and in sensory modalities other than vision occur after
blast in our model and are also rescued by SMM-189 treatment
requires further study.
Neuronal Loss and Rescue in BLA and
Relation to Fearfulness
We previously reported that mild TBI with our model causes
an increase in fearfulness as assessed in an auditory fear
conditioning paradigm, as well as a reduction in the Thy1+
neurons of BLA (as determined from confocal microscopy), and
that both are rescued with SMM-189 treatment (Reiner et al.,
2015). The increased fearfulness manifests as both an increase in
freezing (freezing being the standard indicator of fear in rodents)
to a learned auditory fear stimulus that signals impending shock,
and an enhancement of contextual fear when the mice are placed
in the fear-training chamber (Heldt et al., 2014). Moreover, the
TBI mice exhibit greater resistance to extinction of the learned
fear, in that more extinction trials are needed to extinguish the
learned fear response than is the case for sham blast mice. The
fear is perseverative and progressive, as contextual fear persists
and learned fear is even more resistant to extinction in TBI
mice at 1 year after blast (Heck et al., 2015). In the present
study, stereological neuron counts showed a 33.3% loss of the
Thy1+ fear-suppressing pyramidal neurons and a 42.1% loss of
PARV+ fear-suppressing interneurons in BLA, but no significant
loss of the fear-promoting Thy1-negative pyramidal neurons
of BLA. Together, these findings help explain the increased
fearfulness occurring in our TBI model, as preferential loss of
fear-suppressing neurons should lead to increased fear responses.
Moreover, SMM-189 treatment significantly reduced the Thy1
and PARV neuron loss in BLA, with the rescue of these neuron
types most likely representing the means by which SMM-189
reduces post-TBI fearfulness.
The amygdala contributes to fear via the interplay of three
cell groups, BLA, the lateral anterior nucleus (LA), and the
central nucleus (CeA) (Figure 8; Ehrlich et al., 2009; Ciocchi
et al., 2010; Morozov et al., 2011; Janak and Tye, 2015). The LA
and BLA each contain about 90% excitatory pyramidal neurons
and about 10% GABAergic inhibitory interneurons. The CeA
consists mainly of GABAergic inhibitory neurons, some of which
are projection neurons while others are local circuit neurons.
Fear associations are learned by LA neurons via their inputs
from sensory and pain regions. Learned fear is then signaled to
BLA neurons that activate an intrinsic fear circuit in the CeA
that provides output to various brainstem sites mediating the
affective, autonomic and motor components of fear behavior.
This fear output from BLA appears to occur via Thy1-negative
pyramidal neurons that receive input from LA neurons that
FIGURE 8 | Circuit diagram of neuron types of amygdala of interest to
the present study. Neurons and inputs shown in green promote fear, while
those shown in red reduce fear. Dotted lines represent connections that are
less firmly established in the literature than are the connections shown by solid
lines.
learn to associate a neutral stimulus with a given aversive event.
These Thy1-negative fear-promoting neurons in BLA project to
GABAergic neurons of CeA that promote fear (Herry et al., 2008;
Haubensak et al., 2010; Jasnow et al., 2013; Herry and Johansen,
2014; Lüthi and Lüscher, 2014). By contrast, the Thy1-enriched
pyramidal neurons in BLA suppress fear and project to CeA
neurons that suppress fear. BLA in rodents appears to receive its
main excitatory drive via cortical inputs from different parts of
the ventral medial prefrontal cortex (mPFC), which is specialized
for the integration of emotional states with environmental
stimuli. Projections from the fear-promoting prelimbic part of
mPFCmainly target the fear-promoting pyramidal BLA neurons,
while the fear-reducing infralimbic part of mPFC targets fear-
suppressing pyramidal neurons and GABAergic inhibitory BLA
interneurons (Rosenkranz and Grace, 2001; Paré et al., 2004;
Herry et al., 2008; Jasnow et al., 2013). To better understand how
mild TBI increases fearfulness, and how SMM-189 rescues this
deficit, it would be valuable to know how the inputs from the
prelimbic and infralimbic parts of mPFC, as well as the input
from ventral hippocampus, to BLA are affected by mild TBI.
The BLA contains four major types of GABAergic
inhibitory interneurons constituting about 10% of its total
neuronal population - a parvalbuminergic (PARV) type, a
somatostatinergic (SST) type, a large-sized type containing
cholecystokinin (CCK), and a small-sized type containing
vasoactive intestinal polypeptide (VIP) (Rainnie et al., 2006;
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Muller et al., 2007). The PARV interneurons primarily target
pyramidal BLA neurons, making up half of their inhibitory
input (Muller et al., 2006; Wolff et al., 2014), with the other
types of interneurons providing the other half (Mascagni and
McDonald, 2003; Muller et al., 2003, 2007). Both the PARV
interneurons (Godavarthi et al., 2014; Wolff et al., 2014) and
the CCK interneurons (Truitt et al., 2009) appear to reduce fear
and anxiety, while the SST interneurons appear to increase fear
(Wolff et al., 2014). One simple way in which PARV and CCK
interneurons may reduce fear and anxiety, and SST neurons may
increase fear, is if the PARV and CCK interneurons preferentially
innervate the Thy1-negative fear-promoting BLA neurons, and
SST interneurons preferentially innervate the Thy1-rich fear
suppressing neurons of BLA. Future studies will be needed to
characterize the connectivity of these other interneuron types
with pyramidal neurons, and to determine how each type is
affected by mild TBI, to more fully understand how mild TBI
increases fearfulness, and how SMM-189 treatment produces its
rescue of fearfulness.
Microglial Activation and SMM-189
Therapy
We previously showed that the axonal injury in major fiber
tracts resulting from blast in our TBI model is accompanied
by microglial activation along those fiber tracts and in brain
regions where the damaged axons terminate (Guley et al.,
2016). It is known that injured axons and their myelin sheaths
release molecules that can bind to damage-associated molecular
pattern molecule receptors, which include Toll-like receptors
expressed on microglia, thereby activating them (Kumar and
Loane, 2012). The activated microglia then typically release pro-
inflammatory factors that have toxic effects on nearby neurons,
may help recruit other immune cells to the region, and can
compromise the integrity of the blood-brain barrier, leaving the
central nervous system vulnerable to molecules in the systemic
circulation (Brown and Vilalta, 2015; Loane and Kumar, 2016).
Thus, an initial injury has the potential to lead to a continuing
cascade of deleterious effects. Our present finding that blast TBI
yields substantial neuron loss in cortex, striatum, and amygdala
thus indicates that the initial trauma and the cascade it initiates
leads not only to axonal injury but also neuron loss, perhaps in
some cases secondary to axonal injury.
The rapid upregulation of CB2 by microglia after TBI allows
them to be specifically targeted by SMM-189 for therapeutic
purposes. Our prior in vitro analysis has shown that SMM-189
biases microglia from a pro-inflammatory M1 phenotype to a
pro-healing M2 phenotype (Presley et al., 2015; Reiner et al.,
2015). In addition, we have previously shown that treatment
with SMM-189 reduces microglial activation in the right optic
tract and retina, as assessed with IBA1 immunolabeling, and
biases microglia away from the M1 state toward the M2 state,
as indicated by increased pCREB immunolabeling (Reiner et al.,
2015; Guley et al., 2016). In the present study, we have extended
this observation to several additional brain regions, including
BLA, the striatum, the terminal projection field of the striatum
in the substantia nigra pars reticulata, and the white matter
tract passing from cerebral cortex to brainstem. In all cases,
microglia in these regions in blast-only mice rarely possessed
evident nuclear pCREB, whereas in the SMM-189-treated mice,
all the microglia showed prominent nuclear pCREB staining.
Interestingly, the CD68 immunolabeling revealed some rod-like
microglia in the internal capsule in mice with blast plus SMM-
189, all with prominent nuclear pCREB. The presence of rod-
like microglia is of interest because we have previously shown
that SMM-189 promotes a rod-like morphology in microglia in
vitro (Presley et al., 2015). Moreover, others have demonstrated
that rod-shaped microglia show increased M2 marker expression
after stable alignment with their substrate (Tam and Ma, 2014),
suggesting that such microglia play a role in repairing nervous
system damage.
Overall then, our results show that SMM-189 acts on brain
microglia and biases them to the beneficial M2 state in the
brain regions (and/or their fiber tracts) where SMM-189 rescues
TBI-related neuron loss. Our present finding that SMM-189
treatment for the 2 weeks after blast yields substantial neuron
rescue in cortex, striatum, and amygdala thus indicates that M1
microglial activation during the aftermath of mild TBI worsens
the outcome, and that biasing toward M2 microglial activation
during this same time period allows the survival of many of
the neurons that would have otherwise died. It is likely that the
observed neuronal rescue contributed to the reduction of motor
deficits and fearfulness that mild TBI normally produces. Note
that treatment with a CB2 agonist instead would reduce M1
activation but not promote M2 activation, which may explain
why CB2 agonists have not consistently shown strong benefit
in treating TBI (Mechoulam et al., 2002; Meyer et al., 2010;
Elliott et al., 2011; Amenta et al., 2012, 2014; Firsching et al.,
2012). Our results thus support further testing of CB2 inverse
agonists as a useful therapeutic approach for reducing neural
injury and functional deficits after mild TBI. It is possible that
further optimization of dosage and timing would produce even
greater benefit than we found here and that there is a critical
time window during which treatment would be most effective.
It will also be important to extend testing the efficacy of SMM-
189 to additional neuronal populations and functions in our
TBI model, as well as determine its usefulness in other TBI
models.
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